S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501

被引：5

作者：

Fukuda, Minoru ^{[1
]}

Funaki, Soichiro ^{[2
]}

Yamazaki, Takuya ^{[3
]}

Sato, Shuntaro ^{[4
]}

Mukae, Hiroshi ^{[5
]}

Takenoyama, Mitsuhiro ^{[6
]}

Fukuoka, Junya ^{[7
]}

Nabeshima, Kazuki ^{[8
]}

Tateyama, Hisashi ^{[9
]}

Ashizawa, Kazuto ^{[10
]}

Hara, Masaki ^{[11
]}

Seto, Takashi ^{[6
]}

Okumura, Meinoshin ^{[12
,13
]}

Sugio, Kenji ^{[14
,15
]}

机构：

[1] Nagasaki Univ Hosp, Clin Oncol Ctr, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[2] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Osaka, Japan

[3] Nagasaki Univ, Grad Sch Biomed Sci, Dept Radiol, Nagasaki, Japan

[4] Nagasaki Univ Hosp, Clin Res Ctr, Nagasaki, Japan

[5] Nagasaki Univ, Grad Sch Biomed Sci, Dept Resp Med, Nagasaki, Japan

[6] Natl Hosp Org Kyusyu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan

[7] Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol, Nagasaki, Japan

[8] Fukuoka Univ, Dept Pathol, Fac Med, Fukuoka, Japan

[9] Kasugai Municipal Hosp, Dept Pathol, Kasugai, Aichi, Japan

[10] Nagasaki Univ, Grad Sch Biomed Sci, Dept Clin Oncol, Nagasaki, Japan

[11] Nagoya City West Med Ctr, Dept Radiol, Nagoya, Aichi, Japan

[12] Osaka Toneyama Med Ctr, Osaka, Japan

[13] JART, Osaka, Japan

[14] Oita Univ, Fac Med, Dept Thorac & Breast Surg, Oita, Japan

[15] LOGiK, Fukuoka, Japan

来源：

THORACIC CANCER | 2020年 / 11卷 / 03期

关键词：

Cisplatin; radiotherapy; S-1; thymic carcinoma; PHASE-II; CHEMOTHERAPY; CANCER;

D O I：

10.1111/1759-7714.13319

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S-1 treatment is effective against thymic carcinoma. S-1 plus cisplatin with concurrent radiotherapy is a commonly used treatment for other malignancies, including non-small cell lung cancer (NSCLC). In addition, its safety has been confirmed, and it has been reported to have a marked effect against thymic carcinoma. Therefore, we conducted a phase II study of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced thymic carcinoma, in which the overall response rate was employed as the primary endpoint. The secondary endpoints were overall survival, progression-free survival, and safety.

引用

页码：693 / 696

页数：4

共 50 条

[21] Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma: A Phase II Study
Xintong Wang
Xiaomeng Liu
Dakun Li
Xinlei Wang
Wei Huang
Baosheng Li
Annals of Surgical Oncology, 2019, 26 : 1886 - 1892
[22] A Phase 1 Study of Gemcitabine and S-1 Concurrent Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Matsumura, Yuji
Suyama, Masafumi
Sai, Jinkan
Kubokawa, Yoshihiro
Kamiya, Takayoshi
Watanabe, Sumio
PANCREAS, 2011, 40 (05) : 799 - 800
[23] Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer
Kaira, Kyoichi
Tomizawa, Yoshio
Yoshino, Reiko
Yoshii, Akihiro
Matsuura, Masana
Iwasaki, Yasuki
Koga, Yasuhiko
Ono, Akihiro
Nishioka, Masaki
Kamide, Yosuke
Hisada, Takeshi
Ishizuka, Tamotsu
Shirai, Katsuyuki
Ebara, Takeshi
Saitoh, Jun-ichi
Nakano, Takashi
Sunaga, Noriaki
LUNG CANCER, 2013, 82 (03) : 449 - 454
[24] Combination chemotherapy with S-1 plus cisplatin for advanced urachal carcinoma
Tsuruoka, K.
Sasada, S.
Shimomura, A.
Shimoi, T.
Kodaira, M.
Yunokawa, M.
Yonemori, K.
Shimizu, C.
Fujiwara, Y.
Tamura, K.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S514 - S515
[25] Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer
Tetsuhiko Taira
Kiyotaka Yoh
Seisuke Nagase
Kaoru Kubota
Hironobu Ohmatsu
Seiji Niho
Masakatsu Onozawa
Tetsuo Akimoto
Yuichiro Ohe
Koichi Goto
Cancer Chemotherapy and Pharmacology, 2018, 81 : 565 - 572
[26] Efficacy of S-1 with concurrent radiotherapy (IMRT) and maintenance therapy with S-1 for locally advanced pancreatic cancer
Watanabe, Hiroyuki
Nomura, Yoshikatsu
Ueda, Teruyuki
Sanada, Taku
Notsumata, Kazuo
Toya, Daishu
Kikuchi, Yuzo
Konishi, Shota
Miyayama, Shiro
Sudo, Yoshiko
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 257 - 258
[27] Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer
Taira, Tetsuhiko
Yoh, Kiyotaka
Nagase, Seisuke
Kubota, Kaoru
Ohmatsu, Hironobu
Niho, Seiji
Onozawa, Masakatsu
Akimoto, Tetsuo
Ohe, Yuichiro
Goto, Koichi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (03) : 565 - 572
[28] A Randomized Phase II Study of S-1 and Cisplatin vs. Vinorelbine and Cisplatin with Concurrent Radiotherapy for Locally Advanced NSCLC: WJOG5008L
Shimizu, Junichi
Kodaira, Takeshi
Seto, Takashi
Sasaki, Tomonari
Yamanaka, Takeharu
Kunitake, Naonobu
Ohyanagi, Fumiyoshi
Kozuka, Takuyo
Takeda, Masayuki
Nakamatsu, Kiyoshi
Takahashi, Toshiaki
Harada, Hideyuki
Yoshimura, Naruo
Tsutsumi, Shinichi
Kitajima, Hiromoto
Kataoka, Masaaki
Nakagawa, Kazuhiko
Nishimura, Yasumasa
Nakanishi, Yoichi
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S286 - S286
[29] Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
Choi, Y. J.
Chung, J. S.
Shin, H-J
Cho, G. J.
Wang, S. G.
Lee, B. J.
Cho, B. M.
Joo, Y. D.
Sohn, C. H.
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2008, 122 (08): : 848 - 853
[30] A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer
Shinchi, Hiroyuki
Maemura, Kosei
Mataki, Yuko
Kurahara, Hiroshi
Sakoda, Masahiko
Ueno, Shinichi
Hiraki, Yoshiyuki
Nakajo, Masayuki
Natsugoe, Shoji
Takao, Sonshin
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2012, 19 (02) : 152 - 158

← 1 2 3 4 5 →